Jun 17, 2026 | UniQure AMT-130 Surges 70% on FDA Reversal; Jazz-AbCellera $4.1B TCE Deal

Enbrel Price Cap Blocked: One Ruling That Could Reshape States Drug Pricing

Federal court blocks Colorado's 70% price cap on Enbrel — ruling could shut down state drug pricing laws nationwide. Plus: Casgevy label expansion to age 2 for SCD/TDT sends CRISPR Therapeutics surging 8%. Moderna mFLUSIVA rally hits 70% ahead of August 5 FDA decision. AstraZeneca-CSPC $1.7B kidney deal; Celea raises $180M for IPF; Orca Bio prices Tregzi at $428K. Visit us at www.thepharmcloseout.com pharma, biotech, FDA, clinical trials, drug approvals, Enbrel, Amgen, drug pricing, Casgevy, CRISPR Therapeutics, Moderna, sickle cell disease

Roche Divarasib Beats Both KRAS G12C Rivals in Phase 3 Lung Cancer Study

Roche's divarasib beats both KRAS G12C rivals on PFS and OS in head-to-head Phase 3, hitting survival significance at interim. AstraZeneca returns to CSPC in a $1.7B siRNA kidney disease deal; Abivax surges on $920M raise and cleared obefazimod cancer concerns; Ipsen acquires Memo Therapeutics; BridgeBio secures $1B; Scribe Therapeutics files for IPO; FDA CBER gene therapy leadership transition. Visit us at www.thepharmacloseout.com Roche's divarasib beats both KRAS G12C rivals on PFS and OS in head-to-head Phase 3, hitting survival significance at interim. AstraZeneca returns to CSPC in a $1.7B siRNA kidney disease deal; Abivax surges on $920M raise and cleared obefazimod cancer concerns; Ipsen acquires Memo Therapeutics; BridgeBio secures $1B; Scribe Therapeutics files for IPO; FDA CBER gene therapy leadership transition.

July 01, 2026| Tregzi Approved — Orca Bio Opens a New Lane in Cell Therapy

FDA approves Orca Bio's Tregzi — the first precision-engineered cell therapy for allogeneic transplant, sparking IPO speculation. Plus BridgeBio secures $1B from Sixth Street and KKR at a 100%+ conversion premium, Ipsen's $2.55B deal spree continues with Memo Therapeutics,Merck scraps Alzheimer's drug MK-1167 as AlzeCure lands a $2.2B QuantumCell partnership, and FDA warns Sanofi's Genzyme over Altuviiio production.   Visit us at www.thepharmacloseout.com pharma, biotech, FDA, clinical trials, drug approvals, OrcaBio, Tregzi, BridgeBio, Ipsen, Merck, Alzheimer's, cell therapy

Jun 30, 2026 | NEJM Retracts Tavneos Pivotal Trial; Ionis Tryngolza PDUFA Today

NEJM retracts Amgen's ADVOCATE study after FDA findsendpoint data for 9 patients re-evaluated post-unblinding. Plus: Ionis faces the Tryngolza sNDA PDUFA in severe hypertriglyceridemia, AbbVie's Epkinly delivers chemo-free PFS in R/R DLBCL, Ipsen acquires Kartos for up to $1.75B,and Roche enters the TED race with Enspryng Priority Review. Visit us at www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Tavneos, avacopan,Amgen, NEJM retraction, ADVOCATE study, olezarsen, Tryngolza, IonisPharmaceuticals, epcoritamab, Epkinly, AbbVie, Genmab, DLBCL, Enspryng,satralizumab, Roche, thyroid eye disease, Ipsen, Kartos Therapeutics,navtemadlin, myelofibrosis, Zymeworks, Theravance, ZORYVE, roflumilast,Arcutis, Foundayo, orforglipron, Eli Lilly, Gilead, efzimfotase alfa,AstraZeneca, hypophosphatasia, FDA PreCheck, Lilly, Regeneron

Jun 26, 2026 | FDA Approves Viridian for Thyroid Eye Disease; Merck KGaA's $11.3B Bio-Techne Deal

FDA breaks Amgen's Tepezza monopoly with Viridian's Lumvoa approval in thyroid eye disease. Plus Merck KGaA's $11.3B Bio-Techne acquisition, Biogen gutting the Apellis pipeline post-$5.6B deal, CHMP moves to revoke Tavneos, and Lilly's orforglipron PDUFA lands Monday. Www.thepharacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Viridian Therapeutics, Lumvoa, veligrotug, thyroid eye disease, Amgen, Tepezza, Merck KGaA, Bio-Techne, Biogen, Apellis, Syfovre, Eli Lilly, orforglipron, Moderna, Ionis, Tryngolza, Ardelyx, Xphozah, Sanofi, Tavneos, avacopan, CHMP, Keytruda, Padcev, Replimune, Lycia, Dr. Reddy's, Gilead, AbbVie, M&A, GLP-1, Lilly, Merck, J&J